1ST Source Bank Sells 1,035 Shares of Johnson & Johnson (NYSE:JNJ)

1ST Source Bank lessened its position in Johnson & Johnson (NYSE:JNJ) by 1.4% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 70,980 shares of the company’s stock after selling 1,035 shares during the period. Johnson & Johnson accounts for 0.6% of 1ST Source Bank’s investment portfolio, making the stock its 25th biggest position. 1ST Source Bank’s holdings in Johnson & Johnson were worth $10,265,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in the company. Swedbank AB increased its holdings in Johnson & Johnson by 5.3% during the third quarter. Swedbank AB now owns 2,215,108 shares of the company’s stock valued at $358,980,000 after buying an additional 111,570 shares during the last quarter. Principal Financial Group Inc. grew its stake in Johnson & Johnson by 10.5% during the third quarter. Principal Financial Group Inc. now owns 3,472,312 shares of the company’s stock valued at $562,723,000 after acquiring an additional 329,473 shares in the last quarter. United Bank grew its stake in Johnson & Johnson by 5.6% during the third quarter. United Bank now owns 3,788 shares of the company’s stock valued at $614,000 after acquiring an additional 202 shares in the last quarter. Seizert Capital Partners LLC lifted its position in Johnson & Johnson by 1.0% during the third quarter. Seizert Capital Partners LLC now owns 244,057 shares of the company’s stock valued at $39,552,000 after purchasing an additional 2,441 shares during the last quarter. Finally, Accredited Investors Inc. lifted its position in Johnson & Johnson by 4.0% during the third quarter. Accredited Investors Inc. now owns 7,901 shares of the company’s stock valued at $1,280,000 after purchasing an additional 301 shares during the last quarter. Institutional investors own 69.55% of the company’s stock.

Insider Activity at Johnson & Johnson

In related news, VP Robert J. Decker sold 6,999 shares of Johnson & Johnson stock in a transaction dated Tuesday, February 25th. The stock was sold at an average price of $165.88, for a total transaction of $1,160,994.12. Following the transaction, the vice president now directly owns 21,001 shares of the company’s stock, valued at $3,483,645.88. The trade was a 25.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Timothy Schmid sold 403 shares of Johnson & Johnson stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $156.15, for a total value of $62,928.45. Following the transaction, the executive vice president now directly owns 15,098 shares in the company, valued at approximately $2,357,552.70. The trade was a 2.60 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 0.16% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on JNJ shares. Citigroup lowered their target price on shares of Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating for the company in a report on Wednesday, December 11th. Guggenheim reiterated a “neutral” rating on shares of Johnson & Johnson in a report on Monday, March 10th. Leerink Partners cut their target price on shares of Johnson & Johnson from $182.00 to $169.00 and set an “outperform” rating on the stock in a research report on Thursday, January 23rd. Argus raised shares of Johnson & Johnson to a “strong-buy” rating in a research report on Friday, January 24th. Finally, Stifel Nicolaus cut their price objective on shares of Johnson & Johnson from $170.00 to $155.00 and set a “hold” rating on the stock in a research report on Thursday, January 23rd. Nine equities research analysts have rated the stock with a hold rating, eight have given a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, Johnson & Johnson presently has an average rating of “Moderate Buy” and a consensus price target of $171.33.

Johnson & Johnson Stock Down 0.0 %

JNJ opened at $162.94 on Monday. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.11 and a quick ratio of 0.86. The stock has a market capitalization of $392.29 billion, a price-to-earnings ratio of 24.50, a price-to-earnings-growth ratio of 2.56 and a beta of 0.47. The business has a 50-day moving average of $154.98 and a two-hundred day moving average of $156.27. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $169.99.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.99 by $0.05. The business had revenue of $22.52 billion during the quarter, compared to analysts’ expectations of $22.44 billion. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. The company’s revenue for the quarter was up 5.3% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.29 EPS. On average, research analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th were given a dividend of $1.24 per share. This represents a $4.96 annualized dividend and a dividend yield of 3.04%. The ex-dividend date of this dividend was Tuesday, February 18th. Johnson & Johnson’s dividend payout ratio is currently 74.59%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.